Pilot Study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer
Not Applicable
- Conditions
- Pediatric hepatoblastoma and hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000021931
- Lead Sponsor
- Kanagawa children's medical center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Active infection controls. Congenital or Acquired immunodeficiency syndrome AIDS . Determined ineligible by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method